Cooley's 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024 | Cooley LLP : vimarsana.com

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. While the year saw...

Related Keywords

Germany , United States , German , American , Concentra Biosciences , Bristol Myer Squibb , Dechra Pharma , Astrazeneca , Syneos Health , Merck Kga , Care Health , Novartis , Pfizer , Merck Kgaa , Amgen , Bristol Myers Squibb , American Association For Cancer Research , Cerevel Therapeutics , Gracell Biotechnologies , Carmot Therapeutics , Horizon Therapeutics , Federal Trade Commission , American Association , Cancer Research , Option Care Health , Revolution Medicines , Elliott Investment Management , Patient Square Capital , Veritas Capital , Tang Capital Partners , Tang Capital ,